In addition to isoflurane, the study involves other medications like propofol and midazolam, which are commonly used for sedation in intensive care settings. The purpose of the study is to assess how effective inhaled isoflurane is in improving outcomes for these patients, specifically looking at survival rates and the number of days patients can breathe without the help of a ventilator within 28 days of starting ECMO support.

The study will follow patients for up to 28 days, monitoring various outcomes such as survival, the need for heart transplants or additional heart support devices, and the number of days patients are free from ECMO, inotropes (medications that help the heart pump more effectively), and intensive care. It will also track the use of other sedative medications and any side effects that may occur. The trial aims to provide valuable information on the best sedation practices for patients with severe heart conditions requiring advanced life support.

Participants in the study will receive either norepinephrine alone or a combination of norepinephrine and dobutamine. Both medications are given through an infusion, which means they are delivered directly into the bloodstream. The study will monitor changes in blood lactate levels over a period of 72 hours to see which treatment is more effective. In addition to lactate levels, the study will also look at other outcomes, such as the need for additional medical support and changes in a health score called the SOFA score, which helps assess the severity of a patient’s condition.

The purpose of this study is to better understand which treatment option may be more beneficial for patients with cardiogenic shock. By comparing the effects of norepinephrine and dobutamine, researchers hope to find the most effective way to support the heart and improve patient outcomes during this critical condition.

The study is designed to compare the effects of Istaroxime with a placebo, which is a substance with no active medication. Participants in the trial will be randomly assigned to receive either Istaroxime or the placebo. The main goal is to see if Istaroxime can safely and effectively raise the systolic blood pressure, which is the pressure in the arteries when the heart beats, in patients with cardiogenic shock. The trial will also look at other outcomes, such as the need for additional medications to support heart function and the number of days patients are alive and out of the hospital within a month of starting the treatment.

Participants will be monitored closely throughout the study, which will last for a short period, with the main focus on the first few days after treatment begins. The trial will help determine if Istaroxime can be a beneficial treatment option for people suffering from cardiogenic shock, potentially improving their recovery and overall health outcomes.

Participants in the study will receive either levosimendan or a placebo, in addition to the standard treatment they are already receiving for their condition. The study will monitor the participants over a period of time to see if there are any differences in outcomes such as survival rates, the need for additional life support, or dialysis, which is a treatment that helps clean the blood when the kidneys are not working properly. The goal is to determine if levosimendan can improve the overall health and recovery of patients with cardiogenic shock.

The study will follow participants for up to 30 days initially, with additional follow-ups at 90 days, 180 days, and 12 months to assess long-term effects. Researchers will look at various health indicators, including the number of days patients are free from certain medications, the length of hospital stays, and any major cardiovascular events like heart attacks or strokes. This information will help determine the effectiveness and safety of levosimendan in treating cardiogenic shock.

The research examines the use of noradrenaline, a medication given through an intravenous infusion to raise blood pressure in patients with cardiogenic shock. The study aims to determine if using lower doses of noradrenaline to maintain a lower blood pressure target leads to better outcomes compared to standard treatment.

During the study, participants will be divided into two groups. One group will receive the standard blood pressure treatment, while the other group will receive treatment aimed at maintaining a lower blood pressure target with reduced noradrenaline use. The study will track the survival of patients and their kidney function over a 30-day period after treatment begins.

During the study, participants will receive Levosimendan through an infusion, which is a way of delivering medication directly into the bloodstream. The study will compare the effects of Levosimendan with those of a placebo. Researchers will monitor changes in heart function and blood flow over a period of time, using a technique called Doppler echocardiography, which is a type of ultrasound that shows how blood flows through the heart. The study will also look at other factors, such as changes in blood pressure and overall survival rates.

The trial will last for a specific period, during which participants will be closely observed to gather data on how well Levosimendan works in improving heart function and aiding in the removal of ECMO support. The results of this study could provide valuable insights into the potential benefits of Levosimendan for patients with cardiogenic shock who are undergoing ECMO treatment.

The purpose of the study is to compare the effects of starting empagliflozin early, in addition to the usual treatment, versus the usual treatment alone. The study will last for about three months. During this time, researchers will look at several important health outcomes, such as survival rates, the need for rehospitalization, heart function, and kidney function. Participants will be randomly assigned to receive either empagliflozin along with their usual care or just the usual care without empagliflozin.

Throughout the study, doctors will monitor participants’ heart and kidney health, as well as other factors like weight and liver function. The goal is to see if adding empagliflozin to the treatment plan can improve the overall health and recovery of patients with cardiogenic shock. This research could provide valuable insights into new ways to support patients with this challenging condition.

The purpose of this study is to evaluate how well this combination of medications works in preventing blood clots and reducing the risk of bleeding in patients undergoing a procedure called PCI (Percutaneous Coronary Intervention), which is often used to treat heart attacks. The study will monitor patients to see if the treatment effectively prevents clotting issues and minimizes bleeding problems. Patients will receive cangrelor and bivalirudin, with the doses adjusted based on specific tests that measure how well the blood is clotting.

Throughout the study, the focus will be on ensuring the safety and effectiveness of the treatment. The study will track any occurrences of blood clots or bleeding events while patients are receiving cangrelor. The goal is to find a balance where the treatment is effective in preventing clots without causing significant bleeding. This research aims to improve the care and outcomes for patients with severe heart conditions requiring advanced support like VA-ECMO.

The purpose of the study is to compare the effects of continuing heart stimulation with Dobutamine and Milrinone against the effects of slowing the heart rate with Esmolol Hydrochloride. This will help determine which approach is safer and more effective for patients with cardiogenic shock. Participants will be randomly assigned to receive either the heart-stimulating medications or the heart-slowing medication. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects accurately.

The study will monitor changes in heart rate and other heart functions over a period of time. Participants will receive their assigned treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The trial will last for a maximum of 14 days, during which various heart-related measurements will be taken to assess the impact of the treatments. The goal is to find the best strategy to manage heart function in patients with cardiogenic shock who are supported by V-A ECMO.